KTE-X19

DRUG2 trials

Sponsors

Kite, A Gilead Company, Christian Schmidt, MD

Conditions

Mantle Cell LymphomaRelapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory Mantle Cell Lymphoma

Phase 2

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Active, not recruitingNCT06253663

Kite, A Gilead CompanyRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory Mantle Cell Lymphoma

Start: 2024-03-18End: 2027-07-01Updated: 2026-06-25

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

RecruitingNCT06482684

Christian Schmidt, MDMantle Cell Lymphoma

Start: 2024-02-15End: 2031-12-31Target: 150Updated: 2024-07-01

Related Papers

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.

2025-06-01

Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Blood2024-11-052 citations

<i>Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?</i>

Blood2024-11-05

Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy

Blood2024-11-05